Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive Thymoglobulin for GVHD prevention
NCT01994824Phase 2Terminated
- Sponsor
- University of Calgary
- Start
- Jan 2014
- Primary completion
- Jun 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin in graft-versus-host disease (GVHD), sponsored by University of Calgary. Started Jan 2014; status: terminated.
02
Drugs
antithymocyte globulin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01994824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994824.